|
| Press Releases |
|
 |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS |
| Eisai Co., Ltd. announced today that it has received orphan drug designation for ultrahigh-dose mecobalamin, with a prospective indication for delaying the progression of disease and functional impairment of amyotrophic lateral sclerosis (ALS), by the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Tuesday, May 10, 2022 |
|
|
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) under the accelerated approval pathway. more info >> |
|
|
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan |
| Eisai Co., Ltd. today announced that it has initiated preparation on a New Drug Application for ultrahigh-dose mecobalamin. more info >> |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
| Tuesday, March 22, 2022 |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season 
Dec 25, 2024 08:00 HKT/SGT
|
|
|
From Visionary Talks to Futuristic Robots: VAP Group's Global Blockchain Show Dazzles Dubai
Dec 25, 2024 07:36 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 25, 2024 07:25 HKT/SGT
|
|
|
VAP Group's Global AI Show Explores the Future of AI with Over 3,000 Participants
Dec 24, 2024 15:40 HKT/SGT
|
|
|
The 25th World LNG Summit & Awards will take place on 2-5 December 2025 in Istanbul, Turkiye
Dec 24, 2024 15:30 HKT/SGT
|
|
|
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
Dec 24, 2024 15:20 HKT/SGT
|
|
|
Hitachi delivers a turnkey rail solution for Ho Chi Minh City's first urban railway Line 1 in Vietnam
Dec 24, 2024 13:19 JST
|
|
|
Nissan and Honda sign MOU to consider business integration
Dec 24, 2024 11:18 JST
|
|
|
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive Year
Dec 24, 2024 11:00 JST
|
|
|
Nissan, Honda, and Mitsubishi Motors sign MOU on collaborative considerations
Dec 24, 2024 10:54 JST
|
|
|
GAC Honda Begins Operation of New Energy Vehicle (NEV) Production Factory in Guangzhou, China
Dec 24, 2024 10:23 JST
|
|
|
Sarawak Premier Makes Inaugural Visit to Mitsubishi Power's Takasago Hydrogen Park
Dec 24, 2024 10:10 JST
|
|
|
Kincora Announces Closing of Private Placement, Performance Rights Exercise and Shares for Services
Dec 24, 2024 06:59 HKT/SGT
|
|
|
Revolutionize Your Business Plan: How Ai is Making Entrepreneurship Easier
Dec 23, 2024 21:48 HKT/SGT
|
|
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
